Distribution of pneumococcal serotypes in adult pneumococcal pneumonia cases: Filling the evidence gap to inform vaccination policies

Journal of Infectious Diseases

Volumn 208, Issue 11, 2013, Pages 1734-1736

  Griffin, Marie R ^a,b,c   Grijalva, Carlos G ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Diagnosis; Pneumococcal pneumonia; Pneumococcal vaccine; Vaccination

Indexed keywords

MONOCLONAL ANTIBODY; PNEUMOCOCCAL CONJUGATE VACCINE 7; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; HUMAN; KIDNEY CONCENTRATING CAPACITY; LOBAR PNEUMONIA; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; URINE ANTIGEN DETECTION;

DIAGNOSIS; PNEUMOCOCCAL PNEUMONIA; PNEUMOCOCCAL VACCINE; VACCINATION;

COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE;

EID: 84888608138     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit510     Document Type: Review

References (14)

1. Dochez AR, Avery OT. The elaboration of specific soluble substance by pneumococcus during growth. J Exp Med 1917; 26:477-93.
2. Sherwin RL, Gray S, Alexander R, et al. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with communityacquired pneumonia. J Infect Dis. 2013; 208: 1813-20.
3. Pride MW, Huijts SM, Wu K, et al. Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotypespecific polysaccharides in human urine. Clin Vaccine Immunol 2012; 19:1131-41.
4. Tillett WS, Goebel WF, Avery OT. Chemical and immunological properties of a speciesspecific carbohydrate of pneumococci. J Exp Med 1930; 52:895-900.
5. Sorde R, Falco V, Lowak M, et al. Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy. Arch Intern Med 2011; 171:166-72.
6. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32-41.
7. Bartlett JG. Diagnostic tests for agents of community-acquired pneumonia. Clin Infect Dis 2011; 52(Suppl 4):296-304.
8. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: A time-series analysis. Lancet 2007; 369:1179-86.
9. Griffin MR, Zhu Y, Moore MR, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013; 369:1-10.
10. Huijts SM, Pride MW, Vos JM, et al. Diagnostic accuracy of a serotype specific antigen test in community-acquired pneumonia. Eur Respir J 2013. doi:10.1183/09031936.00137412.
11. Bewick T, Sheppard C, Greenwood S, et al. Serotype prevalence in adults hospitalised with pneumococcal non-invasive community- Acquired pneumonia. Thorax 2012; 67: 540-5.
12. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; 1:CD000422.
13. French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812-22.
14. Hak E, Grobbee DE, Sanders EA, et al. Rationale and design of CAPITA: A RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008; 66:378-83.